Consolidation chemotherapy with FOLFOX
PreclinicalSmall molecule
Consolidation chemotherapy with FOLFOX is one of 30 small molecule programs targeting Chemoradiotherapy. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Chemoradiotherapy
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Eloxatin
TevaPhase 3
Imjudo
AstraZenecaPhase 3
Taxol
TevaPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Paraplatin
AAvyxa
Phase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Alimta
SShawn Eagle
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital Tuebingen